about
Oxcarbazepine versus carbamazepine monotherapy for partial onset seizuresPreclinical antiepileptic actions of selective serotonin reuptake inhibitors--implications for clinical trial designTherapeutic safety monitoring: what to look for and when to look for it.Strategies for optimizing antiepileptic drug therapy in elderly people.Teratogenic effects of antiepileptic drugsNewer therapies in the drug treatment of epilepsy.Second generation anticonvulsant medications: their use in children.Antiepileptic drug treatment in children.Sodium channel blockers for the treatment of neuropathic pain.Pharmacotherapy for children and adolescents with epilepsy.Neuronal nicotinic receptors in sleep-related epilepsy: studies in integrative biology.Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy.Acute oxcarbazepine overdose in an autistic boy.Oxcarbazepine in focal epilepsy and hepatic porphyria: a case report.Oxcarbazepine does not suppress cortical spreading depression.Possible reduction in posttraumatic stress disorder symptoms with oxcarbazepine in a patient with bipolar disorder.Analysis of oxcarbazepine and the 10-hydroxycarbazepine enantiomers in plasma by LC-MS/MS: application in a pharmacokinetic study.Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine.Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers.Antiepileptic drugs and pregnancy outcomes.
P2860
Q24239996-294BAA82-DBF3-4C13-9E7A-440D5275D544Q26850811-96B1D1B6-90B5-4987-8555-140CDB7EA3CDQ33335206-7476116F-4561-4013-96E3-E59E19D64955Q34118987-BA33F81C-AE27-4BB1-8E43-FD7D23322225Q34267151-48652B7A-811B-47AE-8AB2-7B033D903F95Q34509364-CF65FA69-1AEC-4E6C-81AD-3784D46DE1BDQ34555652-331A18ED-258F-456C-98E8-27CE0A4A1B6FQ36730668-A17A7AE1-BCB7-4E4C-9C26-C7F8E4B59E7EQ37605350-89E054D0-28DC-460B-AB92-ED2BFB4D1ADDQ37826193-90204B91-71FA-4D09-9995-21A89B31FCCDQ38477044-3F1A377E-C331-492A-893C-2CAC3F9219EFQ39143986-044CA48A-D5FF-4A36-B8D2-A9B241E4502AQ43122951-7240B88C-5D88-4AAC-AABA-DB7CF2D14914Q43650822-22ABC2AC-C487-4316-9943-045D1109FF4AQ44769570-29E6BE4A-FCA5-4264-A324-40FA23BFE231Q45103295-A48DADDB-6215-436D-8618-A141C2344037Q45172659-339EFACC-322A-469D-8BC9-FFE8BBDE8135Q46624949-DB5C0721-8F65-4C42-B5CF-C3D1589C9B18Q53301415-B34D7C63-D189-40E5-9DCF-28E25C933111Q55716842-A2790EBA-767F-4FD5-A92F-94B68E7ED427
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Oxcarbazepine.
@ast
Oxcarbazepine.
@en
type
label
Oxcarbazepine.
@ast
Oxcarbazepine.
@en
prefLabel
Oxcarbazepine.
@ast
Oxcarbazepine.
@en
P2860
P1433
P1476
Oxcarbazepine.
@en
P2093
E S Tecoma
P2860
P304
P356
10.1111/J.1528-1157.1999.TB00918.X
P478
40 Suppl 5
P577
1999-01-01T00:00:00Z